Abstracts tagged "B cells"

Abstract Number: 1946 • 2014 ACR/ARHP Annual Meeting
CD22 Is Required for Formation of Memory B Cell Precursors within Germinal Centers
Craig Chappell, Kevin Draves and Edward Clark, Immunology, University of Washington, Seattle, WA
Background/Purpose CD22 is a sialic-acid binding co-receptor expressed primarily on B cells that has a number of functions including adhesion, regulation of B cell homeostasis and…
Abstract Number: 999 • 2014 ACR/ARHP Annual Meeting
Microrna-155 As an Epigenetic Regulator of B-Cell Activation in Rheumatoid Arthritis: In Vivo and in Vitro Evidences
Stefano Alivernini¹, Barbara Tolusso¹, Silvia Canestri¹, Luca Petricca¹, Clara Di Mario², Elisa Gremese¹ and Gianfranco Ferraccioli¹, ¹Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ²Division of Pathology, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: MicroRNAs (miRs) are a novel class of post-transcriptional regulators. miR-155 was shown to be a regulator of B cell biology in haematological diseases as…
Abstract Number: 2873 • 2014 ACR/ARHP Annual Meeting
Epratuzumab Induces Broad Inhibition of B Cell Receptor Proximal Signaling but Has Opposing Effects on Distal Signaling in B Cell Subsets: A Profile of Effects on Functional Immune Signaling By Single Cell Network Profiling
Alison Maloney¹, Drew Hotson², Stephen Rapecki¹, Gianluca Fossati¹, Simon Lumb¹, David Rosen², Santosh Putta², Nikil Wale², David Spellmeyer², Alessandra Cesano², Rachael Hawtin² and Anthony Shock¹, ¹UCB Pharma, Slough, United Kingdom, ²Nodality Inc., South San Francisco, CA
Background/Purpose Epratuzumab is a humanized monoclonal antibody targeting the B cell-specific protein CD22 and is in Phase 3 clinical trials in patients with systemic lupus…
Abstract Number: 1945 • 2014 ACR/ARHP Annual Meeting
Pharmacodynamic Effects of the CD22-Targeted Monoclonal Antibody Epratuzumab on B Cells in Patients with Systemic Lupus Erythematosus
Anthony Shock¹, Brian Kilgallen², Willem Koetse², Christian Stach³, Sabine Bongardt³ and Catrinel Galateanu⁴, ¹UCB Pharma, Slough, United Kingdom, ²UCB Pharma, Raleigh, NC, ³UCB Pharma, Monheim, Germany, ⁴UCB Pharma, Brussels, Belgium
Background/Purpose Epratuzumab is a humanized monoclonal antibody (mAb) that targets the B cell-specific protein CD22 and is currently in Phase 3 clinical trials in patients…
Abstract Number: 998 • 2014 ACR/ARHP Annual Meeting
β2 Adrenoceptor Signal Is Augmented in B Cells in the Course of Arthritis to Increase IL-10
Georg Pongratz¹, Clemens Wiest², Madlen Melzer² and Rainer Straub³, ¹Internal Medicine I, University Hospital Regensburg, Regensburg, Germany, ²University Hospital Regensburg, Regensburg, Germany, ³Internal Medicine, University Hospital Regensburg, Regensburg, Germany
Background/Purpose Splenic B cells from collagen-induced arthritis (CIA) mice react to a β2-adrenoceptor (AR) stimulus with increased IL-10 production and adoptive transfer of these cells…
Abstract Number: 2836 • 2014 ACR/ARHP Annual Meeting
Effects of Blisibimod, an Inhibitor of B Cell Activating Factor, on Patient Reported Outcomes and Disease Activity in Patients with Systemic Lupus Erythematosus
Michelle Petri¹, Renee S. Martin², Colin Hislop², Morton A. Scheinberg³ and Richard Furie⁴, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Anthera Pharmaceuticals Inc, Hayward, CA, ³Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil, ⁴Division of Rheumatology and Allergy-Clinical Immunology, North Shore - Long Island Jewish Health System, Great Neck, NY
Background/Purpose: To conduct secondary endpoint analyses of the effects of subcutaneously-administered blisibimod (A-623, AMG 623), an inhibitor of B-cell activating factor (BAFF), on patient-reported outcomes and…
Abstract Number: 1944 • 2014 ACR/ARHP Annual Meeting
Targeting CD22 with Epratuzumab Impacts Cytokine Production By B Cells
Vanessa Fleischer^1,2, Julia Sieber^1,2, Sarah J. Fleischer^3,4, Anthony Shock⁵, Guido Heine⁶, Capucine Daridon^1,2 and Thomas Dörner^1,2, ¹CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ²German Rheumatism Research Centre Berlin, Berlin, Germany, ³Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology/German Rheumatism Research Center (DRFZ), Berlin, Germany, ⁴Department of Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ⁵UCB Pharma, Slough, United Kingdom, ⁶Department of Dermatology, Venerology and Allergology, Charité University Medicine Berlin, Berlin, Germany
Background/Purpose CD22 is a negative co-receptor of the B-cell receptor (BCR) and, when targeted by epratuzumab, partially inhibits BCR signaling, for example by reducing Syk…
Abstract Number: 995 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients Have Alterations in Inherently Autoreactive 9G4+ B-Cell Subpopulations in Peripheral Blood
Rita A. Moura^1,2, Maria J. Leandro³, Venkat Reddy¹, João E. Fonseca^2,4 and Geraldine Cambridge³, ¹Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ²Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ³Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁴Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisbon, Portugal
Background/Purpose B-cells utilizing the VH-region immunoglobulin gene VH4-34 produce natural autoreactive antibodies. The rat monoclonal antibody 9G4 recognizes B-cells with VH4-34-encoded B-cell receptors (9G4+ B-cells)…
Abstract Number: 2795 • 2013 ACR/ARHP Annual Meeting
B Cell Derived Cytokines Induce Glomerular Injury in Mice
Alfred Kim¹, Shreeram Akilesh², Jeffrey Miner³ and Andrey Shaw⁴, ¹IM/Div of Rheumatology, Washington Univ School of Med, St. Louis, MO, ²Pathology, University of Washington, Seattle, WA, ³Renal Division, Washington University School of Medicine, Saint Louis, MO, ⁴Pathology & Immunology/HHMI, Washington University School of Medicine, Saint Louis, MO
Background/Purpose: Renal involvment remains the leading cause of mortality for SLE patients, and is associated with proteinuria and foot process effacement. In subsets of LN…
Abstract Number: 914 • 2013 ACR/ARHP Annual Meeting
Accentuated Expression Of RANKL In Switched Memory B Cells From Patients With Rheumatoid Arthritis
Yuri Hirosaki, Hiroaki Niiro, Shun-ichiro Ota, Naoko Ueki, Hirofumi Tsuzuki, Siamak Jabbarzadeh-Tabrizi, Kumiko Noda, Naoyasu Ueda, Naoyasu Ueda, Atsushi Tanaka, Masahiro Ayano, Sho Ueda, Satomi Hisamoto, Daisuke Oryoji, Mitsuteru Akahoshi, Yojiro Arinobu, Hiroshi Tsukamoto, Takahiko Horiuchi and Koichi Akashi, Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose: Clinical efficacy of B-cell depletion therapy underscores a pathogenic role of B cells in autoimmune diseases such as rheumatoid arthritis (RA). In addition to…
Abstract Number: 28 • 2013 ACR/ARHP Annual Meeting
Differentiation, Activation, and Autoreactivity Of CD11c+ B Cells (ABCs)
Alice E. Wiedeman¹, Natalia V. Giltiay², Lena Tanaka³ and Keith B. Elkon³, ¹Immunology, University of Washington, Seattle, WA, ²Department of Immunology, Division of Rheumatology, University of Washington, Seattle, WA, ³Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Recently, a population of CD11c+ age-associated B cells (ABCs) was identified in normal aged female mice. These cells could be expanded following activation by…
Abstract Number: 2647 • 2013 ACR/ARHP Annual Meeting
Recombinant Monoclonal Antibodies Derived From Single CD19+ Synovial B Cells Of RA Patients With Tertiary Lymphoid Structures Display a Strong Immunoreactivity Towards Citrullinated Histones
Elisa Corsiero¹, Michele Bombardieri², Emanuela Carlotti¹, Hedda Wardemann³, William H. Robinson⁴ and Costantino Pitzalis¹, ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, QMUL, London, United Kingdom, ²Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ³Max Planck Research Group Molecular Immunology, Max Planck Institute for Infection Biology, Berlin, Germany, ⁴Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Rheumatoid arthritis (RA) is characterised by breach of self-tolerance towards citrullinated proteins. Around 40% of patients display synovial tertiary lymphoid structures (TLS) with functional…
Abstract Number: 915 • 2013 ACR/ARHP Annual Meeting
IL-6R Inhibition Reduces Activation Of Different Peripheral Memory B Cell Subsets In RA
Zafar Mahmood¹, Khalid Muhammad¹, Marc Schmalzing², Petra Roll³, Kathrina Eckert¹, Thomas Dörner⁴ and Hans-Peter Tony⁵, ¹Rheumatology and Clinical Immunology, University of Würzburg, Würzburg, Germany, ²Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, ³Rheumatology and Clinical immunology, University of Würzburg, Würzburg, Germany, ⁴CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ⁵Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany
Background/Purpose: Enhanced B cell activity has been proposed as part of the pathogenesis of rheumatoid arthritis also based on the clinical experiences obtained by B…
Abstract Number: 29 • 2013 ACR/ARHP Annual Meeting
A Novel CD27^(-) B-Cell Subset Identified Based On Intracellular Characteristics Is Expanded In SLE
S.J. Fleischer¹, Capucine Daridon² and Thomas Dörner³, ¹Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine Berlin, Berlin, Germany, ²Department of Medicine/Rheumatology and Clinical Immunology, Charité University Medicine / German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany, ³CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Several studies linked the emergence of autoimmunity to abnormalities of the B-cell receptor (BCR) due to disturbances of signaling molecules or its co-receptors. Therefore…
Abstract Number: 2431 • 2013 ACR/ARHP Annual Meeting
Association Of T Follicular Helper / Th17 T Cell and Memory B Cell Populations In Rheumatoid Arthritis With Disease Activity and Therapy With TNF Antagonists
Marc C. Levesque¹, Camilla Macedo², Lisa Boyette², Kevin Hadi³, Erich R Wilkerson⁴, Diana Metes², Larry W. Moreland⁵ and Mandy J. McGeachy⁶, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Univeristy of Pittsburgh, Pittsburgh, PA, ⁴Medicine, University of Pittsburgh, Pittsburgh, PA, ⁵Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Medicine, Division of Rheumatology and Clinical Immunology, Univeristy of Pittsburgh, Pittsburgh, PA
Background/Purpose: Autoreactive memory B cells and T cells contribute to the pathogenesis of rheumatoid arthritis (RA) through production of antibodies and cytokines that activate monocytes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.